No Detail Found!

Efficacy of amitriptyline and duloxetine in post- chikungunya neuropathic pain; a randomized, open- label, cross-over clinical trial

Author(s)
Md Mostafa Kamal Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Md Mizanur Rahman Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Shahrina Sharmin Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Dilip Kumar Bhowmick Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Md Shafiqul Islam Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Akhtaruzzaman AKM Department of Anesthesia, Analgesia and Intensive Care Medicine, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka-1000, Bangladesh
Abstract
A significant number of chikungunya virus infected people develop neuropathic pain lasting for months to years. Patients with neuropathic pain are difficult to treat with conventional analgesics and frequently require antidepressant and anticonvulsant medications. The current study compared the efficacy of amitriptyline and duloxetine in the treatment of post-chikungunya neuropathic pain. Methodology: In this randomized, cross-over, clinical trial, a total of forty patients were enrolled and randomly assigned to either amitriptyline or duloxetine for four weeks followed by a two-week washout period. Then the patients were crossed-over to the next phase which lasted for another four weeks. Amitriptyline was given in doses of 10, 25, and 50 mg and duloxetine was given in 20, 30, and 60 mg once daily at 8.00 PM respectively with optional dose up-titration. Pain relief was measured by VAS (visual analogue scale) after one, two, three, and four weeks in each phase as a primary outcome, and improvement of quality of life was assessed by SF-36 (short form-36) at the beginning and end of each phase as a secondary outcome. Results: A total of twenty one patients completed both treatment phases out of forty patients. The reduction of pain intensity was significant in both amitriptyline and duloxetine groups compared with their baseline values (p 0.336). The quality of life (SF-36) was significantly improved with both amitriptyline and duloxetine (p 0.324). Regarding adverse events, dry mouth was significantly more common in the amitriptyline group than the duloxetine group (p < 0.013). Conclusion: Amitriptyline and duloxetine can be used in the treatment of post-chikungunya neuropathic pain effectively, but duloxetine is preferred because of its less adverse effects.
Publication Details
Page(s) 647-652
Published Journal: Anaesthesia, Pain and Intensive Care, Volume: 25, Issue: 5, Year: 2021

Request the full text from PASTIC

Keywords
Neuropathic pain, Quality of life, Duloxetine, Chikungunya, SF-36, Amitriptyline
0

Citations

0

Downloads

116

Views